血清CK-MB检测在癌性心包积液治疗中的临床意义

目的：探讨血清CK-MB检测在癌性心包积液治疗中的临床价值。方法：以免疫抑制法测定血清CK-MB5次：入院、出院及出院后3月内每月1次。观察组包括54例癌性心包积液，对照组为54例不伴心包积液的癌症患者。结果：观察组血清CK—MB的阳性率高于对照组，分别为79．6％(43／54)和35．18％(19／54)，且在观察组中的降低和／或升高与疗效相关，且差异有显著性；而对照组差分无显著性。结论：血清CK—MB合量与癌细胞浸润心包有关，其对癌性心包积液患者的病情、疗效、复发及预后评估有一定的参考价值。

CLINICAL VALUE OF SERUM CK-MB IN MALIGNANT PERICARDIAL EFFUSION

Objective:To estimate the clinical value of serum CK-MB in patients with malignant pericardial effusion.Methods:Serum CK-MB levels was detected by immunoinhibition assay in observation group including 54 patients with malignant pericardial effusion and 54 tumor patients who have no pericardial effusion as control group,with totally 5 times,which are on the day of admission,discharge,and once every month within 3 months after discharching from the hospital.Results:Serum CK-MB positive rate in observation group was higher than that of the control group,that is 79.6 %(43/54) and 35.18 %(19/54) respectively.Their level decreased and/or increased associated with treatment effect in observation group,there were notable statistic difference (P<0.05),while there were no difference in control group.Conclusion:The contents of CK-MB in sera are closely related to tumor invasion into pericardium.It could be useful in monitoring cancer status,prognosis,recurrence and treatment effect.